Current Rating Overview
On 02 January 2026, Astrazeneca Pharma India Ltd’s rating was revised to Sell from a previous Hold status, with the Mojo Score declining by 17 points from 54 to 37. This adjustment reflects a reassessment of the company’s overall investment appeal based on a comprehensive evaluation of its quality, valuation, financial trend, and technical outlook. Investors should note that while the rating change date is fixed, all subsequent data and performance indicators discussed are current as of 23 March 2026.
Here’s How the Stock Looks Today
As of 23 March 2026, Astrazeneca Pharma India Ltd is classified as a small-cap stock within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Grade remains at Sell, signalling caution for investors considering exposure to this stock at present. The stock has experienced a downward trend in recent months, with returns showing a decline of 1.74% on the day, 2.37% over the past week, and 8.02% in the last month. Over the year-to-date period, the stock has fallen by 9.43%, while the one-year return stands at -4.24%.
Quality Assessment
The company’s quality grade is rated as good, indicating that Astrazeneca Pharma India Ltd maintains solid operational and management standards. This suggests a stable business model and competent governance, which are positive attributes for long-term investors. However, despite this strength, other factors weigh heavily on the overall rating.
Valuation Considerations
Valuation is a critical factor influencing the current Sell rating. Astrazeneca Pharma India Ltd is considered very expensive at present, trading at a price-to-book value of 26. This premium valuation is significantly higher than the average historical valuations of its peers in the pharmaceutical sector. The company’s return on equity (ROE) is a robust 26.1%, which typically justifies a higher valuation, but the elevated price-to-book ratio and a PEG ratio of 6.1 suggest that the stock is priced for exceptionally high growth expectations that may not be fully supported by current fundamentals.
Financial Trend Analysis
The financial grade is assessed as flat, reflecting a lack of significant growth momentum in recent quarters. The latest quarterly results ending December 2025 reveal a 45.6% decline in profit after tax (PAT) to ₹31.55 crores compared to the previous four-quarter average. Additionally, cash and cash equivalents have dropped to ₹399.94 crores, the lowest in the half-year period, while profit before depreciation, interest, and taxes (PBDIT) also hit a low of ₹44.83 crores. Despite a 16.3% increase in profits over the past year, these quarterly results indicate some operational challenges and a cautious outlook on near-term earnings growth.
Technical Outlook
The technical grade for Astrazeneca Pharma India Ltd is bearish. This reflects the stock’s recent price action and momentum indicators, which suggest downward pressure. The consistent negative returns over multiple time frames, including a 10.49% decline over three months and a 6.71% drop over six months, reinforce the technical weakness. Such trends often signal investor sentiment turning cautious or negative, which can influence short-term trading decisions.
Implications for Investors
The Sell rating from MarketsMOJO indicates that Astrazeneca Pharma India Ltd currently presents a higher risk profile relative to its potential rewards. Investors should be mindful of the stock’s expensive valuation, flat financial trends, and bearish technical signals. While the company’s quality remains good, the combination of these factors suggests limited upside and a possibility of further downside in the near term. This rating advises investors to consider reducing exposure or avoiding new positions until more favourable conditions emerge.
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, valuation and growth prospects vary widely. Astrazeneca Pharma India Ltd’s premium valuation contrasts with its recent earnings softness, which may not align with the sector’s broader performance. Investors comparing this stock to peers should weigh the company’s operational strengths against its stretched price multiples and subdued financial momentum.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Summary
In summary, Astrazeneca Pharma India Ltd’s current Sell rating reflects a cautious stance based on its very expensive valuation, flat financial performance, and bearish technical indicators, despite maintaining good quality fundamentals. Investors should carefully consider these factors in the context of their portfolios and risk tolerance. The stock’s recent price declines and subdued earnings growth suggest that patience and prudence are warranted before considering new investments in this company.
Looking Ahead
Market participants should monitor upcoming quarterly results and sector developments closely. Any improvement in earnings momentum, valuation rationalisation, or technical reversal could alter the stock’s outlook. Until then, the current rating advises a defensive approach.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
